Clinical trial
Sirolimus and Thymoglobulin to Prevent Kidney Transplant Rejection
NCT00006178 · National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), NIH · Completed
Key facts
| NCT number | NCT00006178 |
|---|---|
| Title | Sirolimus and Thymoglobulin to Prevent Kidney Transplant Rejection |
| Official title | Sirolimus Monotherapy to Optimize Activation Induced Cell Death (AICD) in Renal Transplants Following Lymphocyte Depletion Induction With Thymoglobulin |
| Lead sponsor | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Kidney Failure |
| Intervention type | Drug |
| Interventions | Sirolimus, Thymoglobulin |
| Enrollment | 12 |
| Start date | Aug 1, 2000 |
| Primary completion | Dec 1, 2007 |
| Completion | Dec 1, 2007 |
| First posted | Aug 16, 2000 |
| Last update posted | Sep 17, 2019 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: